Cargando…

P4 COVID19-associated fungal infections

PLENARY SESSION 4, SEPTEMBER 22, 2022, 2:00 PM - 2:45 PM:    : Coronavirus disease 2019 (COVID-2019) associated invasive fungal infections (IFIs) have emerged as an important complication in a substantial number of critically ill COVID-19 patients, and three groups of fungal pathogens have increasin...

Descripción completa

Detalles Bibliográficos
Autor principal: Hoenigl, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494467/
http://dx.doi.org/10.1093/mmy/myac072.P4
_version_ 1784793802532192256
author Hoenigl, Martin
author_facet Hoenigl, Martin
author_sort Hoenigl, Martin
collection PubMed
description PLENARY SESSION 4, SEPTEMBER 22, 2022, 2:00 PM - 2:45 PM:    : Coronavirus disease 2019 (COVID-2019) associated invasive fungal infections (IFIs) have emerged as an important complication in a substantial number of critically ill COVID-19 patients, and three groups of fungal pathogens have increasingly been recognized as causes of superinfections: Aspergillus, Mucorales, and Candida. First reports of cases and case series of COVID-19-associated pulmonary aspergillosis (CAPA) have emerged during the first months of the pandemic. Prevalence rates varied widely due to the fact that CAPA was, and still remains, challenging to diagnose in patients with COVID-19-associated acute respiratory failure (ARF). The clinical picture and radiological findings of CAPA are unspecific and the primarily airway invasive growth in non-neutropenic patients and the late occurrence of angioinvasion in the course of the disease may complicate diagnosis. Current guidelines recommend treatment of CAPA during its early airway invasive phase, which may result in some overtreatment (i.e., treatment in patients that may not develop angioinvasive infection), given the independent contribution of CAPA to devastating mortality rates of around 50% that have been shown in multiple studies. This talk will also review the incidence of COVID-19-associated IFIs caused by Mucorales, and Candida, including C. auris, and will discuss—clinical risk factors, predisposing changes in the host environment, and immunological mechanisms involved in the pathogenesis of these coinfections, as well as current and future diagnostics and treatments.
format Online
Article
Text
id pubmed-9494467
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-94944672022-09-26 P4 COVID19-associated fungal infections Hoenigl, Martin Med Mycol Oral Presentations PLENARY SESSION 4, SEPTEMBER 22, 2022, 2:00 PM - 2:45 PM:    : Coronavirus disease 2019 (COVID-2019) associated invasive fungal infections (IFIs) have emerged as an important complication in a substantial number of critically ill COVID-19 patients, and three groups of fungal pathogens have increasingly been recognized as causes of superinfections: Aspergillus, Mucorales, and Candida. First reports of cases and case series of COVID-19-associated pulmonary aspergillosis (CAPA) have emerged during the first months of the pandemic. Prevalence rates varied widely due to the fact that CAPA was, and still remains, challenging to diagnose in patients with COVID-19-associated acute respiratory failure (ARF). The clinical picture and radiological findings of CAPA are unspecific and the primarily airway invasive growth in non-neutropenic patients and the late occurrence of angioinvasion in the course of the disease may complicate diagnosis. Current guidelines recommend treatment of CAPA during its early airway invasive phase, which may result in some overtreatment (i.e., treatment in patients that may not develop angioinvasive infection), given the independent contribution of CAPA to devastating mortality rates of around 50% that have been shown in multiple studies. This talk will also review the incidence of COVID-19-associated IFIs caused by Mucorales, and Candida, including C. auris, and will discuss—clinical risk factors, predisposing changes in the host environment, and immunological mechanisms involved in the pathogenesis of these coinfections, as well as current and future diagnostics and treatments. Oxford University Press 2022-09-20 /pmc/articles/PMC9494467/ http://dx.doi.org/10.1093/mmy/myac072.P4 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oral Presentations
Hoenigl, Martin
P4 COVID19-associated fungal infections
title P4 COVID19-associated fungal infections
title_full P4 COVID19-associated fungal infections
title_fullStr P4 COVID19-associated fungal infections
title_full_unstemmed P4 COVID19-associated fungal infections
title_short P4 COVID19-associated fungal infections
title_sort p4 covid19-associated fungal infections
topic Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494467/
http://dx.doi.org/10.1093/mmy/myac072.P4
work_keys_str_mv AT hoeniglmartin p4covid19associatedfungalinfections